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5ABBREVIATIONS
aCGH array comparative genomic hybridization
AIDS                                       acquired immunodeficiency syndrome
BAC bacterial artificial chromosome
bp base pairs
BFB breakage fusion bridge
cCGH chromosomal comparative genomic hybridization
cDNA complementary deoxyribonucleic acid
CGH comparative genomic hybridization
CNV copy number variation
DAPI                                       4’,6-diamino-2-phenylindole
DFSP dermatofibrosarcoma protuberans
DNA                                       deoxyribonucleic acid
FISH fluorescence in situ hybridization
FITC fluorescein isothiocyanate
GO                                          gene ontology
kb kilobase
LMS leiomyosarcoma
Mb megabase
MFH malignant fibrous histiocytoma
MLPA multiplex ligation-dependent probe amplification
OS osteosarcoma
qRT-PCR quantitative real-time polymerase chain reaction
RNA ribonucleic acid
SNP                                       single nucleotide polymorphisim
SV40                                       simian virus 40
ULMS                                     uterine leiomyosarcoma
All gene symbols can be found at (http://www.ncbi.nlm.nih.gov/entrez)
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7ABSTRACT
Over the past years, much research on sarcomas based on low-resolution cytogenetic and
molecular cytogenetic methods has been published, leading to the identification of
genetic abnormalities partially underlying the tumourigenesis. Continued progress in the
identification of genetic events such as copy number aberrations relies upon adapting the
rapidly evolving high-resolution microarray technology, which will eventually provide
novel insights into sarcoma biology, and targets for both diagnostics and drug
development.
The aim of this Thesis was to characterize DNA copy number changes that are involved
in the pathogenesis of soft tissue leiomyosarcoma (LMS), dermatofibrosarcoma
protuberans (DFSP), osteosarcoma (OS), malignant fibrous histiocytoma (MFH), and
uterine leiomyosarcoma (ULMS) by applying fine resolution array comparative genomic
hybridization (aCGH) technology.
Both low- and high-grade LMS tumours showed distinct copy number patterns, in
addition to sharing two minimal common regions of gains (15q26-qter and 17p13.1-q11)
and losses (6p12-p21.3 and 13q14.3-qter). Small aberrations were detected by aCGH,
which were beyond the resolution of chromosomal comparative genomic hybridization
(cCGH). DFSP tumours analysed by aCGH showed gains in 17q (100%), 22q (43%), and
21 additional gained regions, but only one region (22q) with copy number loss. Recurrent
amplicons identified in OS by aCGH were 12q11-q15, 8q, 6p12-p21, and 17p. Amplicons
12q and 17p were further characterized in detail. Possible target genes identified within
amplicon 12q were OS9, CYP27B1, DKFZP586D0919, and TSFM. Genes such as
COX10, PMP22, ADORA2B, ZNF287, MRIP, COPS3, PEMT, SREBF1, TOM1L2,
TOP3A, GRAP, and MAPK7 were considered as possible targets harboured within the
17p amplicon.
The amplicon at 17p was characterized by aCGH in low- and high-grade LMS, OS, and
MFH. In all but one case this amplicon, with minimal common regions of gains at 17p11-
p12, started with the distal loss of 17p13-pter. OS and high-grade LMS were grouped
together as they showed a complex pattern of copy number gains and amplifications at
17p, whereas MFH and low-grade LMS showed a continuous pattern of copy number
gains and amplification at 17p. In addition to the commonly gained (1p, 1q, 2p, 3p, 6p,
8q, 10q, 18q) and lost regions (2q, 4q, 6p, 6q, 7p, 7q, 13q, 14p, 16q, 19p, Xp, Xq)
identified in ULMS by aCGH, various biological processes affected by these copy
number changes were also indicated by pathway analysis. The most interesting and
statistically significant pathways which might contribute to tumourigenesis in ULMS
were the G1/S transition of the mitotic cycle, co-translational protein targeting to
membranes, actin filament polymerization, positive regulation of cytokine biosynthesis,
DNA replication, chromatin modification, telomere maintenance, meiosis, mitosis, and
angiogenesis.
The three novel findings obtained in this work were: characterization of amplicon 17p in
low- and high-grade LMS and MFH, profiles of DNA copy number changes in LMS, and
detection of various pathways affected by copy number changes in ULMS. These studies
have not been undertaken previously by aCGH technology, thus this Thesis adds new
information regarding DNA copy number changes in sarcomas.
8In conclusion, the aCGH technique used in this Thesis has provided new insights into the
genetics of sarcomas by detecting the precise regions affected by copy number changes
and some potential candidate target genes within those regions, which had not been
uncovered by previously applied low resolution techniques. The candidate genes
identified here can be thus be used for further studies for understanding the genetic
causes underlying sarcomas.
9INTRODUCTION
Numerous genetic alterations such as gene copy number changes, point mutations, and
both numerical and structural chromosomal alterations underlie the development of
cancer. In the majority of cases the development of cancer is mainly due to somatically
acquired alterations, whereas a minority develop due to an inherited predisposing
genotype.
Sarcomas are a heterogeneous group of rare malignancies of mesenchymal origin
accounting for approximately 1% of all malignancies. They are divided into two major
types: bone and soft tissue sarcomas. These tumours occur mostly in the long bones,
extremities, trunk, retroperitoneum and abdomen. Sarcomas are uncommon even though
soft tissue and bone comprise almost two thirds of the mass of the human body. In
Finland, with a population of 5.2 million inhabitants, bone and soft tissue sarcomas
comprise less than 1.5% of all new cancers diagnosed during 1953-2000 (data obtained
from the Finnish Cancer Registry Database). Based on previous comparative genomic
hybridization (CGH) and cytogenetic studies, sarcomas can be divided into two major
groups: one group possessing simple karyotypes including translocations, and the other
characterised by complex karyotypes (Borden et al. 2003).
Cytogenetic and molecular genetic techniques such as G-banding, FISH, quantitative real
time PCR, and cCGH have lead to enhanced diagnostic accuracy, especially when
tumours display overlapping clinicohistopathological features or unusual phenotypes. For
example, supernumerary ring chromosomes are frequently present as the sole karyotypic
abnormality in well-differentiated liposarcoma, myxoid malignant fibrous histiocytoma
and parosteal osteosarcoma. This abnormality may be used as a marker to differentiate
the tumours from other types of liposarcoma, malignant fibrous histiocytoma and
osteosarcoma. Over the past years many tumour-specific alterations have been detected
by cytogenetic and molecular methods, thus providing accurate diagnosis in cases where
the histological appearance is uncertain or confusing (Busam and Fletcher 1997; Lazar et
al. 2006).
Chromosomal imbalances are frequently found in sarcomas. These alterations have been
detected previously by standard cytogenetic analysis and chromosomal comparative
genomic hybridization (cCGH), where the resolution of each method is at the level of
chromosomal bands. It is suggested that tumour suppressor genes are located within
regions showing DNA copy number losses whereas oncogenes are found in regions
showing DNA copy number gains/amplifications (Snijders et al. 2003). Thus, genome-
wide gene copy number analysis is crucial for cancer genetics for the identification of
target oncogenes and tumour suppressor genes that are involved in the multi-step process
of cancer development. In this Thesis, array comparative genomic hybridization (aCGH)
was applied to analyse sarcomas due to the ability of this technique to determine the copy
number changes at the gene level. aCGH, a high-throughput and high-resolution
technique, has the potential in the near future to be used routinely for research and
diagnostic purposes in detecting gene copy number imbalances.
Previous studies of sarcoma have identified recurrent chromosomal regions of
amplifications and losses (see review of Knuutila et al. 1998, 1999, and references
therein). But the knowledge of the target oncogenes and tumour suppressor genes
involved in the copy number changes is still limited, although it’s essential for better
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understanding of the biology behind sarcomas. The aim of this Thesis was to apply the
high resolution aCGH technology in order to identify and characterize the copy number
changes, and the genes within those regions that remained undetected by low resolution
methods, that are involved in the pathogenesis of sarcomas.
REVIEW OF THE LITERATURE
1. SARCOMAS
1.1. Soft tissue sarcomas
Soft tissue sarcomas are defined clinically and histologically as a heterogeneous group of
malignant neoplasms of mesenchymal origin. They develop in connective tissues other
than bone, such as skeletal muscle, fat, tendons, fibrous tissue, smooth muscle and the
neurovascular elements that support these components (Enzinger and Weiss 2001b). Soft
tissue sarcomas occur in a wide variety of anatomical sites. The majority arise in lower
extremities (59%), trunk (19%), retroperitoneum (15%), and head and neck (9%), with a
slightly higher incidence in males. Sarcomas metastasize most frequently to the lungs
(Cormier and Pollock 2004). Metastatic spread to lymph nodes is rare except in synovial
sarcoma and rhabdomyosarcoma where there is a significant risk for lymph node
metastasis (Conrad and Enneking 1990). Soft tissue sarcomas are generally classified
according to the resemblance of the tumour to the normal cell type. The most accepted
classification system for soft tissue sarcoma is that of the World Health Organization
(Fletcher et al. 2002).
The grade of the tumour is an estimator for the degree of sarcoma malignancy.
Histological parameters used for the grading of the soft tissue sarcomas provide
information regarding prognostic prediction, metastatic risk and treatment. Currently, the
most widely used grading systems are the French 3-step grading (French Federation of
Cancer Centers) and National Cancer Institute grading (Coindre 2006; Guillou et al.
1997; Gustafson et al. 2003; Oliveira and Nascimento 2001; van Unnik et al. 1993). The
former is based on tumour differentiation, mitotic index and tumour necrosis whereas the
latter takes into account the histologic type and subtype, location and the amount of
tumour necrosis, and for some tumour types cellularity, nuclear pleomorphisim, and
mitotic index. Reproducibility, validity, risk management and prognostic capabilities
could be improved in a future grading system by incorporation of the advances in
imaging techniques, molecular genetics and determination of  genome wide expression of
oncogenes and tumour suppressor proteins (Oliveira and Nascimento 2001).
The incidence rate of the different types of soft tissue sarcomas varies among different
reports (Table 1). However, the incidences of the most common soft tissue sarcomas
according to Hashimoto et al (1992) were malignant fibrous histiocytoma (MFH)
(25.1%) and liposarcoma (11.6%), followed by rhabdosarcoma (9.7%), leiomyosarcoma
(LMS) (9.1%), synovial sarcoma (6.5%), malignant schwannoma (5.9%), and
fibrosarcoma (5.2%). The etiology of soft tissue sarcomas is relatively poorly understood.
The implicated etiologic agents are genetic, environmental and iatrogenic factors (therapy
associated), but there is no conclusive evidence to support such claims (Conrad and
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Enneking 1990). Radiation-induced sarcomas in adults are rare, mainly observed after
radiotherapy treatment for breast, prostate, and cervical cancer (Mark et al. 1994;
Mertens et al. 2000; Travis 2002). However, radiation-induced sarcomas in childhood are
the most frequent secondary cancers (Menu-Branthomme et al. 2004). The most common
radiation-induced soft tissue sarcomas are MFH, osteosarcoma (OS), fibrosarcoma, and
rarely malignant peripheral nerve sheath tumour and angiosarcoma (Mark et al. 1994;
Wiklund et al. 1991).
The role of oncogenic viruses in the development of soft tissue sarcomas is not clearly
known. The involvement of simian virus 40 (SV40) in the development of OS is
controversial (Shah et al. 2004). DNA viruses such as human herpesvirus 8 is a well
known aetiological agent of Kaposi sarcoma in AIDS patients (Rezaee et al. 2006) and
Epstein-Barr virus has been shown to infect smooth-muscle cells in immunodeficient or
immunosuppressed patients, and may thus contribute to the pathogenesis of  LMS  in
children with HIV infection (Jenson et al. 1999).
Traditionally, soft tissue sarcomas are diagnosed with the aid of morphological findings
e.g. by microscopy and immunophenotyping. However, the morphological heterogeneity,
genetic complexity and rare occurrence lead to low validity and non-optimal
reproducibility of the diagnosis and grading (Suehara et al. 2006). At present, microarray
technologies such as gene expression profiling and protein expression studies are being
used for research purposes for the identification of important genes/proteins for the
molecular classification of sarcomas, which might lead to the development of novel
therapeutic strategies (Baird et al. 2005; Suehara et al. 2006).
1.2. Bone sarcomas
The occurrence of bone sarcomas is rare as compared with soft tissue sarcomas. Bone
sarcomas are bimodal regarding their incidence rates and age specific frequencies. The
first incidence peak occurs during the second decade of life, while the second occurs after
the age of 60 (Fletcher et al. 2002). Incidence rates of the most common bone sarcomas
such as OS, chondrosarcoma and Ewing sarcoma are shown in Table 1.
The major malignant bone tumours are OS (31%), chondrosarcoma (31%) and Ewing’s
sarcoma (14%) (Bauer et al. 1999). OS typically occurs in the second decade of life, and
arises in the long bones of extremities. Overall survival rates for OS patients have
improved remarkably after the introduction of preoperative chemotherapy, but have
remained constant over the past 10-15 years, with no substantial improvements (Weber
2005). The incidence rate is age-specific in chondrosarcoma, showing a gradual increase
up to age 75. This is a malignant cartilage-forming tumour of bone, which is frequently
located in the pelvis and femur (Papachristou and Papavassiliou 2007). Since
chemotherapy and radiotherapy have not substantially improved the survival of
chondrosarcoma patients, surgical treatment is so far the only effective form of treatment
(Weber 2005). Tumour grading based on light microscopy analysis is currently the best
prognostic indicator for chondrosarcomas (Bovee et al. 2005; Rozeman et al. 2002). The
most common primary bone tumour seen in children is Ewing sarcoma. Surgery is a
major tool for its treatment, but for patients with localized tumours chemotherapy
increases survival rates from 5% up to 70% and for the metastatic tumours from 25% up
to 30%. Radiotherapy alone or in addition to surgery is also beneficial (Marec-Berard
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and Philip 2004). The less common malignant bone tumours are fibrosarcoma, LMS and
MFH. The most important criteria for the histological grading in bone tumours are
cellularity and the nuclear features of the tumour cells. Mitotic patterns and necrosis are
other additional parameters for grading (Heck et al. 2006).
Table 1: Incidence rates of specific histologic types of soft tissue and bone sarcomas
based on the M.D Anderson Cancer Center (aMDACC in adolescent and young adult and
bMDACC in the total population) tumour registry from 1990-2003 in the U.S.A., and the
Scandinavian Sarcoma Group Register (SSGR) from 1986-1997 (Modified from Herzog
2005).
Soft tissue sarcoma aMDACC bMDACC SSGR
Unclassified and other 22% 22% 11%
Leiomyosarcoma 7% 20% 8%
Malignant fibrous histiocytoma 5% 18% 45%
Liposarcoma 5% 11% 14%
Rhabdomyosarcoma 15% 6% 1%
Synovial sarcoma 16% 6% 7%
Neurofibrosarcoma 5% 2% 5%
Extraosseous Ewing 6% 2% 1%
Epitheliod sarcoma 4% 2% 1%
Alveolar soft-parts sarcoma 4% 1% 1%
Dermatofibrosarcoma protuberans 3% 3% -
Fibrosarcoma 3% 2% 4%
Hemangiopericyoma <1% <1% 1%
Angiosarcoma 4% 5% -
Bone sarcoma aMDACC bMDACC SSGR
Osteosarcoma 57% 45% 31%
Chondrosarcoma 10% 28% 31%
Ewing sarcoma 25% 16% 14%
Malignant fibrous histiocytoma 2% 4% 6%
Other 6% 7% 18%
2. GENETIC CHARACTERISTICS OF SARCOMAS
Alterations seen at the cytogenetic level in sarcomas are generally complex, exhibiting
both numerical and structural aberrations (Skapek and Chui 2000). General features of
the sarcomas studied in this work are shown in Table 2.
On the basis of previous cytogenetic and molecular studies, sarcomas can be genetically
segregated into two different groups. One group has simple karyotypes showing specific
translocations leading to the formation of fusion genes, as shown in Table 3. The other
group has complex karyotypes with numerous structural and numerical changes (Borden
et al. 2003). Sarcomas lacking specific translocations, such as OS, MFH, LMS, and
liposarcoma, possess numerous gains and losses. The biological features that differentiate
sarcomas with and without precise genetic alterations are listed in Table 4. The major
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biological differentiating factor between the two sarcoma types is inactivation of the
TP53 pathway. Alterations in this pathway are rare in sarcomas that display characteristic
translocations, but when present they are associated with decreased survival rates e.g., in
synovial sarcoma, myxoid liposarcoma, and Ewing sarcoma (Borden et  al. 2003).  The
TP53 pathway is always altered in those sarcomas with non-specific alterations, but it has
no or very little value in the prognosis.
Unlike most solid tumours (Aman 1999), translocations are detected in one-third of all
sarcomas (Mitelman 2000), and in some haematological malignancies (Aplan 2006). As
translocation-associated fusion genes are specific for particular sarcoma types they are
used as specific and powerful diagnostic markers. Fusion genes produced by
translocation produce chimeric proteins, most of which encode abnormal transcription
factor/s. Based on cell line studies conducted on various sarcoma types, e.g. alveolar
rhabdomyosarcoma, Ewing sarcoma, and synovial sarcoma (Arvand et al. 2001; Nagai et
al. 2001; Scheidler et al. 1996), it seems evident that the chimeric proteins are oncogenic,
i.e., are capable of promoting uncontrolled cell growth, inhibiting apoptosis, and
promoting tumour formation. Studies of mouse models with alveolar rhabdomyosarcoma
possessing a recurrent translocation t(2;13)(1;13) demonstrated that possessing only the
chimeric transcript is insufficient for tumourigenesis, and that additional genetic changes
are needed as synergetic events for the formation of the tumour (Lagutina et al. 2002).
Table 2: General features of DFSP, LMS, ULMS, MFH and OS.
Sarcoma DFSP LMS ULMS MFH OS
Type Soft tissue Soft tissue Soft tissue Soft tissue Bone
Origin Mesenchymal Mesenchymal Mesenchymal Mesenchymal Bone forming
mesenchymal
cells
Age Not specific,
usually at 30-50
years
Not specific,
usually at 50-
60 years and
also in young
adults and
children
Postmenopausal
women
Late adult life Children
Characteristic
cytogenetic
feature
t(17;22)(q22;13q) Complex
karyotypes
Losses: 10q,
13q
Gains: Xp, 1q,
17p
Complex
karyotypes
Losses: 14q,
22q, 13q, 16q
Gains: 1, 8, 17p,
Xp
Complex
karyotypes,
19p+ marker,
unidentified ring
chromosomes
Losses: 9p, 10q,
13q
Gains: 1q, 17,
20q
Complex
karyotypes
Losses: 2q,
3p, 6q, 8p,
10p
Gains: 8q, 6p,
12q, 17p, 19q
Recurrence Yes Yes Yes Yes Yes
Metastasis Rarely Yes Yes Yes Yes
Cure Surgery Surgery Surgery Surgery Surgery and
chemotherapy
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Table 3: Chromosomal translocations and their associated fusion genes in sarcomas
(Modified from Xia and Barr 2005).
Tumour type Translocation/
Fusion gene
References
Alveolar rhabdomyosarcoma t(2;13)(q35;q14)
PAX3-FKHR
t(1;13)(p36;q14)
PAX7-FKHR
Galili et al. 1993
Davis et al. 1994
Alveolar soft part sarcoma t(X;17)(p11;q25)
TFE3-ASPL
Ladanyi et al. 2001
Angiomatoid fibrous histiocytoma t(12;16)(q13;p11)
FUS-ATF1
Waters et al. 2000
Clear-cell sarcoma t(12;22)(q13;q12)
EWS-ATF1
Zucman et al. 1993a
Dermatofibrosarcoma protuberans t(17;22)(q22;q13)
COL1A1-PDGFB
Simon et al. 1997
Desmoplastic small-round cell tumours t(11;22)(p13;q12)
EWS-WT1
Ladanyi and Gerald 1994
Endometrial stromal sarcoma t(7;17)(p15;q21)
JAZF1-JJAZ1
Koontz et al. 2001
Ewing family tumours t(11;22)(q24;q12)
EWS-FLI1
t(21;22)(q22;q12)
EWS-ERG
t(7;22)(p22;q12)
EWS-ETV1
t(2;22)(q33;q12)
EWS-E1AF
t(17;22)(q12;q12)
EWS-FEV
t(16;21)(p11;q22)
FUS-ERG
Delattre et al. 1992
Zucman et al. 1993b
Jeon et al. 1995
Kaneko et al. 1996
Peter et al. 1997
Shing et al. 2003
Infantile fibrosarcoma t(12;15)(p13;q25)
ETV6-NTRK3
Knezevich et al. 1998
Inflammatory myofibroblastic tumour t(1;2)(q22;p23)
TPM3-ALK
t(2;19)(p23;p13)
TPM4-ALK
t(2;17)(p23;q23)
CLTC-ALK
Lawrence et al. 2000
Lawrence et al. 2000
Bridge et al. 2001
Low grade fibromyxoid sarcoma t(7;16)(q33;p11)
FUS-CREB312
Panagopoulos et al. 2004
Myxoid chondrosarcoma t(9;22)(q22;q12)
EWS-CHN
t(9;17)(q22;q11)
TAF2N-CHN
t(9;15)(q22;q21)
TCF12-CHN
Labelle et al. 1995
Sjogren et al. 1999
Sjogren et al. 2000
Myxoid liposarcoma t(12;16)(q13;p11)
FUS-CHOP
t(12;22)(q13;p12)
EWS-CHOP
Crozat et al. 1993
Panagopoulos et al. 1996
Synovial sarcoma t(X;18)(p11;q11)
SYT-SSX1
SYT-SSX2
SYT-SSX4
Crew et al. 1995
Crew et al. 1995
Skytting et al. 1999
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Table 4: Biological features of sarcomas with or without precise alterations (Modified
from Borden et al. 2003).
Feature Sarcomas with
precise changes
Sarcoma without
precise changes
Karyotypes Often simple Usually complex
Translocations Reciprocal and specific Usually not, or
nonreciprocal and
nonspecific
Average age at diagnosis 27 57
Prevalence of TP53 pathway alterations Relatively low High
Prognostic impact of TP53 pathway
alterations
Strong Weak to moderate
Incidence in bilateral retinoblastoma
and Li-Fraumeni syndrome
Rare Common
Incidence among radiation-induced
sarcomas
Rare Common
Table 5: Mutations causing sarcomas and their diagnostic utility (Slominski et al. 1999).
Gene name Location Sarcoma type Diagnostic
utility
TP53 17p13 Various Possible
Rb1 13q14 Various Possible
CDKN2A 9p12 OS and LMS Possible
RAS Various Various No
In addition to chromosomal-scale abnormalities, the majority of sarcomas show sporadic
point mutations. Table 5 shows the most commonly mutated genes with possible
diagnostic applications. However there is also a subset of sarcomas arising due to
inherited predisposition. For example, Li-Fraumeni syndrome, which is caused by
germline TP53 mutations, predisposes individuals to different types of cancers and
sarcomas of bone and soft tissue in early childhood (Malkin et al.  1990).  Patients  with
hereditary retinoblastoma, harbouring germline mutation in Rb, are susceptible to various
secondary malignancies and are also at increased risk of developing osteogenic sarcomas
(Abramson et al. 1984). Neurofibromatosis type I syndrome, caused by germline
mutation in NF1, leads to the development of neurofibromas and malignant peripheral-
nerve-sheath tumour in a minority of patients (King et al. 2000).
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3. GENERAL FEATURES OF SARCOMAS STUDIED IN THIS THESIS
3.1. Dermatofibrosarcoma protuberans (DFSP)
DFSP is a relatively rare dermal and subcutaneous spindle-shaped neoplasm of
intermediate malignancy. Clinically, DFSP is characterized by aggressive growth
accompanied by a high rate of local recurrence near the same site due to the extensive
infiltrative growth, but it rarely metastasizes. Adverse clinical outcomes are associated
with the fibrosarcomatous transformation of DFSP, which is a form of high-grade tumour
progression (Sandberg and Bridge 2003a; Sirvent et  al. 2003). DFSP can occur in any
part of the body but it usually arises as a firm nodule or plaque on the trunk and proximal
extremities of young to middle age adults, more frequently in males (Enzinger and Weiss
2001a). However, in a recent study the DFSP incidence rates were stated to be higher in
women than in men (Criscione and Weinstock 2006). As shown in Figure 1, the cells of
DFSP are composed of spindle-shaped nuclei arranged in a distinct storiform or
cartwheel growth pattern. The tumour displays low to moderate mitotic activity.
Necrosis,  which  is  a  common  feature  of  MFH,  is  rarely  seen  in  this  tumour  type
(Enzinger and Weiss 2001a). DFSP is distinguished from other spindle cell sarcomas by
its strong CD34 immunopositivity (Sonobe et al. 1999). The current treatment is a wide
local excision (Mendenhall et al. 2004).
Cytogenetically DFSP is characterized by a reciprocal chromosomal translocation
t(17;22)(q22;q13) resulting in the fusion of two genes, COL1A1 and PDGFB, which are
located on chromosomes 17q22 and 22q13, respectively (Pedeutour et al. 1996). This
fusion of the COL1A1 promotor to coding sequence of PDGFB causes the stimulation of
PDGFBR in an autocrine manner, suggested to contribute to the disease development
(Greco et al. 1998; Shimizu et al. 1999; Sjoblom et al. 2001). In one-third of DFSP cases
a supernumerary ring chromosome derived from segments of chromosome 17 and 22 is
also observed (Naeem et al. 1995; Pedeutour et al. 1994; Pedeutour et al. 1995). Other
frequent numerical chromosomal abnormalities seen in DFSP are trisomies of
chromosomes 5 and 8, whereas trisomies of chromosomes 4, 7, 11, 12, 13, 14, 15, 16,
and 18 are seen less frequently (Sirvent et al. 2003).  Figure  2  illustrates  a  DFSP
karyotype.
3.2. Soft tissue leiomyosarcoma (LMS)
LMSs are malignant mesenchymal tumours comprised of cells resembling well-
differentiated smooth-muscle cells. LMS, which accounts for 10% of soft tissue sarcomas
(Enzinger and Weiss 2001c; Hu et al. 2005; Sandberg 2005), occurs in a wide variety of
anatomical locations, and is mainly found in elderly individuals although it may also
develop in young adults and children (Miettinen and Fetsch 2006). The high incidence of
recurrence and metastasis in these aggressive tumours are related to the tumour size and
grade (Wang et al. 2001). LMSs arise mainly in the retroperitoneal space and abdominal
cavity, and around half arise in retroperitoneum of which about two-thirds of cases occur
in women (Enzinger and Weiss 2001c).
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Figure 2: Karyotype of a DFSP tumour with trisomies of chromosomes 4, 5, and 8, and a
ring chromosome (r) indicated by an arrow. “Reprinted from Pedeutour et al (1994),
with permission from Elsevier.”
In contrast to other sarcoma entities, LMSs are very rarely induced by radiotherapy
(Brady et al. 1992; Patel et al. 1999). Histologically the spindle shaped LMS cells
contain elongated cigar-shaped nuclei (Figure 1). The diagnosis of this sarcoma type is
based on immunohistochemical staining with desmin, actin and H-caldesmon (Miettinen
and Fetsch 2006). So far the karyotypes reported in LMSs are complex, diverse, and
incomplete with no common aberrations seen in most or all of the cases (Sandberg 2005)
(Figure 3).
3.3. Uterine leiomyosarcoma (ULMS)
ULMS is a rare aggressive tumour that is more frequent than all other LMSs, and occurs
predominantly in postmenopausal women. It accounts for 1% of all gynecologic
malignancies  and  is  associated  with  an  extremely  poor  prognosis  (Echt et al. 1990;
Matsumura et  al. 2006). The 5-year survival is between 20% and 75% and the rate of
recurrence  ranges  from  45%  up  to  73%  (Giuntoli et al. 2003).  Resistance  to
chemotherapy and radiotherapy makes surgery the primary treatment method for this
sarcoma (Benoit et al. 2005). Therefore, identification of the target genes that are
involved in the pathogenesis is needed in order to develop new therapeutic treatment.
Previously, it has been reported that ULMS may either arise de novo from smooth-muscle
cells of the uterus or from pre-existing uterine leiomyoma (Jatoi 2003; Lee et al. 1994).
The karyotypes of ULMS are very complex, showing both numerical and structural
aberrations.
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Figure 1: Morphological features typical for DFSP, LMS, MFH and OS. A) Spindle
cells, with regular small nuclei infiltrating into subcutaneous fat, representing a typical
DFSP. B) A tumour composed of spindle cells with atypical hyper chromatic nuclei and
eosinophilic cytoplasm representing a high-grade LMS. C) A spindle cell tumour forming
storiform structures representing a MFH. D) A tumour composed of large atypical cells,
surrounded by immature osteoid, representing a high-grade osteoblastic OS. All figures
are stained by Haematoxylin-Eosin, original magnification X 200.
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Figure 3: Inverted DAPI-banded image of a grade III LMS tumour showing complex
rearrangements and numerical aberrations in all chromosomes. “Reprinted from Wang
et al (2001), with permission of Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, Inc.”
3.4. Malignant fibrous histiocytoma (MFH)
MFH is the most common type of soft tissue sarcoma. In the current WHO classification
MFH is now regarded as synonymous with undifferentiated pleomorphic sarcoma
(Fletcher et al. 2002). It is diagnosed in late adult life and occurs as the most common
type of post irradiation sarcoma (Enzinger and Weiss 2001d). This heterogeneous group
of tumours displays a broad range of histological appearances and can be divided into
four subtypes, such as storiform-pleomorphic, myxoid, giant cell, and inflammatory
types.  The  two  first  tumour  types  are  the  most  common  and  the  latter  two  are  rare
(Enzinger and Weiss 2001d). These tumours are usually located in the extremities and
retroperitoneum, and occur in both sexes with a slight predominance in males (Walter et
al. 1997). Although MFH is classified as a soft tissue sarcoma, it may also occur in bone
(Senel et al. 2006; Tarkkanen et al. 2006).
Morphological features of MFH are shown in Figure 1. To date, there is little cytogenetic
data on MFH and the reported karyotypes are complex with numerous numerical and
structural abnormalities (Simons et al. 2000). Structural rearrangements seen in MFH are
ring chromosomes, double minutes, homogenously staining regions, telomeric
associations, dicentric chromosomes, and ploidy changes (Figure 4). Despite a number of
cytogenetic analyses, no consistent chromosomal aberrations have been reported
(Szymanska et al. 1995; Walter et al. 1997). Certain chromosomal abnormalies, such as a
19p+ marker chromosome, may indicate high risk of local recurrence and metastasis
(Simons et al. 2000).
3.5. Osteosarcoma (OS)
OS is the most common nonhaematopoetic malignant bone tumour of children and adults,
deriving from the primitive bone forming mesenchymal cells. The tumour typically arises
in the long bones of the appendicular skeleton such as distal femur, proximal tibia, and
proximal humerus (Sandberg and Bridge 2003b). The incidence of OS is higher in males
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Figure 4: G-band karyotype of a grade IV MFH indicating 46,XY,del(2)(p16),
add(8)(q?),-9,-22,+mar1,+mar2. “Reprinted from Szymanska et al (1995), with
permission from Elsevier.”
with an overall 5-year survival rate ranging between 20% and 70% (Stock et al. 2000).
Histologically OS is a complex mixture of various cell types ranging from spindle cells to
epitheliod or mono- or multinucleated giant cells (Ragland et al. 2002) (Figure 1). OS has
no characteristic recurrent translocation but can be characterized by the occurrence of
complex chromosomal rearrangements exhibiting multiple marker chromosomes, double
minutes, homogenously stained regions, and polyploidy involving various tumour
suppressors and oncogenes (Bridge et  al. 1997; Fletcher et al. 1994; Hoogerwerf et al.
1994). A karyotype of OS is shown in Figure 5. The regions most frequently involved in
chromosomal rearrangements in OS identified by spectral karyotyping are located in
chromosomes 6, 8, 17 and 20 (Bayani et al. 2003; Ozaki et al. 2003).
Due to the heterogeneity or cell-to-cell variation, cytogenetic studies in OS have yielded
conflicting results insufficient for proper diagnosis and for determining the prognosis of
the disease.
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Figure 5: G-banded karyotype from a conventional OS indicating numerous marker
chromosomes and multiple numerical and structural abnormalities.  “Reprinted from
Sandberg and Bridge (2003b), with permission from Elsevier.”
4. MOLECULAR GENETIC ANALYSIS OF SARCOMA
4.1. Copy number changes by comparative genomic hybridization
In contrast with leukaemia and lymphoma where cytogenetic methods have been
successfully applied to investigate chromosomal changes, analysing solid tumours by
conventional cytogenetics is challenging. Tumours cells are difficult to culture and
harvest and the few metaphase spreads obtained are either inadequate or too complex to
determine banding patterns. Chromosomal comparative genomic hybridization (cCGH), a
molecular cytogenetic technique introduced by Kallioniemi and co-workers in 1992,
enabled the comprehensive scanning of DNA copy number changes across the whole
genome at the chromosomal level. CGH analyses on large numbers of tumour samples
enabled the identification of recurrent regions of copy number changes specific for
particular tumour types, leading to the identification of regions containing genes involved
in cancer development (Knuutila et al. 1998; 1999). As illustrated in Figure 6, in cCGH
tumour genomic DNA and reference DNA samples are differentially labeled by nick
translation with different dyes in order to distinguish between the two genomes
hybridized on the metaphase chromosome.
Several disadvantages of cCGH have to be taken into the account while analysing the
results. It cannot detect balanced chromosomal translocations, inversions, polyploidy or
mosaicism. In addition, copy number changes can only be detected when tumour content
of the sample is at least 50%. Aberrations are detected with an approximate resolution of
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5Mb (Kallioniemi et al. 1994). Smaller areas (1Mb) are detectable only if they are highly
amplified (Forozan et al. 1997).
Development of array comparative genomic hybridization (aCGH) has overcome the
limited resolution of cCGH, enabling mapping of changes directly into genomic
sequences and thus detecting the changes at the gene level. As illustrated in Figure 6,
aCGH  is  based  on  the  same  principles  as  cCGH  but  the  DNAs  are  labeled  with
fluorescent dyes by random priming and metaphase chromosomes are replaced by known
genomic sequences (BAC, cDNA clones, or oligonucleotides) with known chromosomal
locations directly spotted onto microscope slides. This approach (aCGH) has paved the
way for higher resolution and specificity of array analysis. In the early applications of
aCGH, large size BAC clones were used which provided sufficiently intense signal for
accurate measurement specifically for detecting single copy number changes and
homozygous deletions (Albertson and Pinkel 2003; Pinkel et al. 1998). Another approach
for performing aCGH comprised of mapped cDNA clones. The use of cDNA arrays for
measuring copy number changes was pioneered by Pollack in 1999.
In cDNA arrays short exonic sequence is spotted onto slides, excluding promoter,
intronic and intergenic sequences. Use of cDNA arrays for aCGH analysis is appealing as
both DNA copy number and expression studies can be done in parallel on the cDNA
platform, thus combining genomic data with expression data to facilitate the
identification of target genes (Hyman et al. 2002; Kauraniemi et al. 2001; Monni et al.
2001; Pollack et al. 2002). Oligonucleotide arrays are the latest approach for performing
aCGH, and allow also the detection of introns and intragenic regions (Barrett et al. 2004;
Brennan et al. 2004; Carvalho et al. 2004). Oligonucleotide array analyses are performed
on very small amounts of DNA (1.5 ?g), which is a limiting factor when using cDNA
arrays  where  20  ?g  of  DNA  is  required  as  starting  material.  Clone  sizes  and  the
corresponding resolution for BAC, cDNA and oligonucleotide arrays are shown in Table
6.
Table 6: Details regarding the size of the spotted clones and the resolution of different
microarray platforms.
Clone type Year of
first
publication
Clone
size
Resolution References
BAC 1998 ~100 kb 1.3 Mb Pinkel et al. 1998
cDNA 1999 ~300 bp 0.1 Mb Pollack et al. 1999
Oligonucleotide 2004    60 bp ~35 kb Barrett et al. 2004
Oligonucleotide aCGH with a dense representation of sequences allows the fine
resolution identification of copy number aberrations at the gene level, and is specifically
used for the detection of microdeletions and very small novel alterations that may be
important for the disease but were not detected by low resolution methods. However,
aCGH still lacks the ability to track balanced translocations that do not lead to copy
number change.
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The most recently developed array platform, single nucleotide polymorphism (SNP)
arrays, offers the ability to characterize simultaneously the copy number changes and loss
of heterozygosity events in a tumour sample (Bignell et al. 2004; Zhao et al. 2004;
Pfeifer et al. 2007). These arrays in the future are likely to be invaluable tools for the
comprehensive characterization of tumours (Dutt and Beroukhim 2007).
Copy number variation (CNV) is ubiquitous, submicroscopic copy number variation of
DNA segments. CNVs include deletions, insertions, and duplications larger than 1kb up
to several Mb. Several thousands of CNVs exist within the human genome and still more
remain to be identified (Freeman et al. 2006; Rendon et al. 2006; Wong et al. 2007). Due
to the ubiquity of CNV in the genome and their presence in genomes of healthy
individuals, discrimination between normal and pathological CNV is very important. At
present all identified CNVs are registered in the Database of Genomic Variants
(http://projects.tcag.ca/variation) (Rendon et al. 2006). While making clinical diagnostic
interpretations CNV should be taken into consideration. aCGH detects only cumulative
but not allele specific CNV. In order to detect CNV inheritance patterns, development of
locus and allele specific quantitative assays for DNA copy number evaluation is needed
(Freeman et al. 2006). In order to precisely interpret the genomic data concerning cancer
and other malignancies precise detection of all CNVs is needed which could be achieved
by high throughput genome mapping and association analysis.
4.2. Application of comparative genomic hybridization in sarcoma genetics
Since the development of cCGH it has been used extensively as a research tool in cancer
genetics. It has been a valuable diagnostic tool for patients with multiple tumours (Weiss
et al. 2003a) and in the differential diagnosis of benign and malignant bone tumours,
where immunohistochemistry was inadequate due to the unavailability of reliable
markers (Gebert et al. 2006). cCGH enabled the detection of tumour specific recurrent
changes and the implication of specific genes in the development of cancer, thus
providing the starting point for the further characterization of the aberrant regions
(Knuutila et al. 1998; 1999). cCGH analysis on MFH of bone, a relatively rare malignant
tumour, supported the concept that bone MFH is an individual bone tumour entity with
characteristic aberration patterns distinct from OS, bone fibrosarcoma, and soft tissue
MFH (Tarkkanen et  al. 2006 ). Some aberrant chromosomal regions are also clinically
relevant, for example gain of 13q in liposarcoma correlates with poor prognosis (Schmidt
et al. 2005). Gain of 12q correlates with poor overall survival rate in adult fibrosarcoma
(Schmidt et al. 2002). Gains in 6p are associated with poor prognosis in Ewing sarcomas
and related tumours (Tarkkanen et al. 1999b). Gains at 8q are assumed as a potential
marker for poor prognosis in high-grade OS (Tarkkanen et al. 1999a) and loss of 10q and
gain of 5p are associated with aggressive outcome in LMS (Hu et al. 2005).
Classification of various cancers based on copy number profiles obtained by aCGH
technology is more informative, for example, in sarcomas, histologically similar tumours
such as GIST and LMS are differentiated based on their copy number profiling by aCGH
(Meza-Zepeda et al. 2006).
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Figure 6: Schematic representation of the comparative genomic hybridization (cCGH
and aCGH) technique (Modified from Snijders et al. 2003). Equal amounts of tumour and
reference DNAs are labeled with different dyes and hybridized onto slides with Cot-1
DNA for blocking the repetitive sequences. cCGH uses metaphase chromosomes as
hybridization targets, whereas aCGH uses genomic sequences on slides. Hybridized
cCGH slides are then analysed by automated digital image analysis software in order to
determine signals indicating chromosomal gains, high-level amplifications and losses. In
aCGH intensity differences in the hybridization patterns indicating gains, high-level
amplifications, losses and homozygous deletions are measured by using appropriate
software for example, CGH analytic software (Agilent Technologies).
In various cancers genomic profiling by aCGH has proven to be a very feasible approach
for accurate diagnosis of the cancer, predicting prognosis, and differentiating between
subsets of tumours, which in the end lead to the proper therapeutic treatments (Callagy et
al. 2005; Weiss et al. 2003b; Wilhelm et al. 2002). In liposarcomas, in contrast to RNA
expression analysis, copy number profiles obtained from aCGH analyses appeared to be
more powerful for discriminating between dedifferentiated and pleomorphic subtypes
(Fritz et al. 2002).
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Genome-wide aCGH has introduced new dimensions in terms of resolution and precision
for detecting DNA copy number changes, thus making it a reliable and powerful method
for detecting disease-associated genes. aCGH analysis is able to detect known unbalanced
translocations with better resolution as compared with cytogenetic methods, which fail to
detect the precise breakpoints. Buckley and coworkers (2002) used aCGH for the
detection of unbalanced translocations in two cases of DFSP. Only by the use of aCGH
has it been shown that cytogenetically balanced translocations are indeed frequently
associated with small gains and losses (Watson et al. 2007), thus highlighting the
usefulness of aCGH for diagnostic, therapeutic and research purposes for defining
translocation breakpoints with precision.
In conclusion, aCGH is a powerful tool for precisely mapping the boundaries of the
amplicon and translocation breakpoints.  The candidate gene within the amplicon could
then be further confirmed based on RNA/protein expression studies which would allow
discrimination between driver genes (which are the target genes) from the passenger
genes (copy numbers of which are changed due to the proximity of driver genes).
The most recurrent DNA copy number changes and putative target genes detected by
both cCGH and aCGH in DFSP, LMS, ULMS, MFH, and OS are shown in Table 7.
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Table 7. Most recurrent copy number changes in sarcomas detected by cCGH and aCGH.
Sarcoma
type
Translocation cCGH References aCGH References Target
genes
DFSP 17;22
(q22;q13)
Gains: 17q, 22q, 8q, 5
Losses: ND
Nishio et al. 2002;
Sirvent et al. 2003
Gains: 8, 5, 22q, 17q, 7p, 18, 21
Losses: 19, 22q
Buckley et al.
2002; Linn et
al. 2003
COL1A1,
PDGFB
 LMS No Gains: 1q21, 4p16, 5p, 12q13-
q14, 17p, 20q13.1, 22q, Xp
Losses: 4q, 11q, 13q, 10q, 2q,
16q, Xq
El-Rifai et al. 1998; Hu
et al. 2005; Otano-Joos
et al. 2000; Sandberg
2005; Svarvar et al.
2006; Wang et al. 2001;
Wang et al. 2003
ND ND ND
ULMS No Gains: 17p, Xp, 1q, 8
Losses: 13q, 10q, 16q, 12p, 2p,
14q, 22q
Hu et al. 2001; Levy et
al. 2000; Packenham et
al. 1997, Svarvar et al.
2006
High-level gains: 7q36.3, 7q33-q35, 12q13-
q15, 12q23.3
Losses: 1p21.1-p21.2, 1p22.3-p31.1,
9p21.2-p22.2, 10q25-q25.2, 11q24.2-q25,
13q12-q12.13, 14q31.1-q31.3, 14q32.32-
q32.33, 15q11-q12, 15q13-q14, 18q12.1-
q12.2, 18q22.1-q22.3, 20p12.1 and
21q22.12-q22.13
Cho et al.
2005
HMGI-C,
MDM2,
SAS,
TIMI,
DCC
MFH t(5;7)(q31;q22),
t(13;14)(q10;q10),
t(1;10) In subset
of case
Gains: 1p31, 9q31, 5p14-pter,
7q32, 7p15-pter, 1q21-q22,
17q23-qter, 20q, 8p21-pter,
12q13-q21, 6q21-q23, 8p21-pter,
8q24-qter, 12q13-q21
Losses: 13q21, 13q22, 9p21-
pter, 10q, 11q23-qter, 13q10-q31
Larramendy et al. 1997;
Simons et al. 2000;
Weng et al. 2004
Gains: 6q21-q23, 8p21-pter, 8q24-qter,
12q13-q21
Losses: ND
Weng et al.
2004
CDKN2A,
RBI,
TP53,
MDM2,
MASL1,
CDK4
OS No Gains: 1q21, 3q26, 4q, 7q31-32,
5p13-14, 6p, 8q, 12q12-13,
14q24-qter, 17p11-12, Xp11.2-
21, Xq12, 20q
Losses: 2q, 3p, 9, 12q, 13q, 14q,
15q, 16, 17p, 18q, 6q, 8p, 10p
Forus et al. 1995;
Hulsebos et al. 1997;
Lau et al. 2004; Stock
et al. 2000; Tarkkanen
et al. 1995; Tarkkanen
et al. 1999a
Gains: 6p, 8q12-q21.3, 8q22-q24, 17p,
1p36.32, 6p21.1, 8q24, 12q14.3, 16p13, X,
1p, 12q
Losses: 17p13, 17p12, 17q12, 6q27,
13q12.2, 13q, 10q,
Lim et al.
2004; Man et
al. 2004;
Squire et al.
2003;
Zielenska et
al. 2004
RBI,
CDK4,
TP53,
MDM2,
SAS,
MYC,
PMP22,
TOP3A,
MAPK7,
COPS3
27
4.3. Quantitative analysis of genetic alterations
Despite the utility of the array methods, definite quantitative results of the genomic
regions are not obtained. Molecular methods for detecting the quantitative genetic
alterations in cancer cells are quantitative real-time polymerase chain reaction (qRT-
PCR), locus specific FISH and multiplex ligation-dependent probe amplification
(MLPA).
qRT-PCR is the most common method used for quantifying nucleic acids (Bustin et al.
2005). It is widely used in diagnostic and research applications for the diagnosis of
tumours, such as in monitoring minimal residual diseases (Marcucci et al. 1998; Krauter
et al. 2001), in identification of micrometastases in neuroblastoma, colorectal cancer, and
prostate cancer (Cheung et al. 2001; Bustin et al. 1999; Gelmini et al. 2001). This
method is also used for the quantification of amplifications of oncogenes (Bieche et al.
1999; Konigshoff et al. 2003). Locus specific FISH is also an effective technique for
determining the number of copies of genes altered. This technique is commonly used to
identify oncogene amplification (Sartelet et al. 2002; Tajiri et al. 1999). The recently
developed MLPA method (Schouton et al. 2002) is used for copy number detection,
methylation quantification, detection of unknown mutations, SNPs, and for mRNA
profiling. This method is applied to a broad range of cancers for research purposes and in
routine diagnostics (Monfort et al. 2006; Rooms et al. 2006). The use of the above
methods not only enhances accuracy of diagnoses of various tumour types but can also be
used for the validation of DNA microarray results.
5. IMPACT OF DNA COPY NUMBER CHANGES
5.1. Oncogene activation by DNA copy number amplifications
Genetic alterations such as DNA copy number amplification and losses are known to be
involved in the activation of proto-oncogenes and in the inactivation of tumour
suppressor genes, respectively. It is well known that accumulation of these genetic
changes disturbs the normal cellular growth controlling mechanism leading to the
development of tumours. Proto-oncogenes are the genes involved in normal cellular
growth and differentiation. Alterations such as chromosomal translocations, point
mutations or gene amplifications can change the proto-oncogenes into active oncogenes,
leading to uncontrolled cell growth and proliferation, and hence to the development of
cancer. Alteration of a single allele is sufficient for the oncogenic effects, as oncogenes
act in a dominant manner. The most frequent location for proto-oncogenes is at or near
chromosomal translocation breakpoints, as shown in Table 3. Proto-oncogene activation
by gene amplification is commonly seen in sarcomas and other cancers. The extent of
gene amplification has proven to be useful for predicting prognosis and targeted
therapies, for example, MYCN amplification in neuroblastoma (Savelyeva and Schwab
2001) and ERBB2 amplification in breast cancer (Al-Kuraya et al. 2004). The percentage
of genes over-expressed due to gene amplification varies between different types of
cancer (Hyman et al. 2002; Pollack et al. 2002; Wolf et al. 2004).
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High level gene amplification can be detected in cytogenetic analysis in the form of
double minutes, homogenously staining regions or ring chromosomes (Cowell 1982).
Amplicons are small chromosomal regions containing multiple copies of amplified DNA
(0.5-10 Mb), whereas larger chromosomal areas showing copy number increases are
considered as gains (Lengauer et al. 1998). Various models for gene amplifications have
been proposed but the exact underlying mechanism is not fully understood. According to
the onion skin (overreplication) model, a replication bubble or overreplicated strands are
formed during the S-phase of mitosis due to multiple points of initiation of DNA
replication in a single cell cycle. The overreplicated strands can be then resolved by
recombination into extrachromosomal elements or linear sequence. However, not all
amplicons display amplification patterns generated by this model (Botchan et al. 1979;
Sambrook et al. 1975). The breakage-fusion-bridge (BFB) model of gene amplification
has explained the genomic instabilities in cancer, and the generation of a variety of gene
amplifications (Albertson et al. 2003; Fenech 2002; Masuda and Takahashi 2002; Von
Hoff 1991). Furthermore, it has also been reported to be responsible for intratumour
genetic heterogeneity (Gisselsson et al. 2000). This model requires a double-strand break
or telomere erosion for its initiation followed by replication and fusion of two uncapped
sister chromatids, resulting in the formation of unstable dicentric chromosomes, thus
leading to another breakage. Many cycles of BFB result in the multiplication of genes
near the break point (Murnane 2006; Myllykangas and Knuutila 2006; Shimizu et al.
2005).
Gene amplification by aCGH can be detected at the gene level where the growth
promoting gene(s) can be seen. As compared to the locus specific FISH, where the exact
number of gene copies can be counted, aCGH does not provide any good estimate or
signal intensity for gains and amplifications and thus the criteria for differentiating gains
from amplifications vary in different reports. The tumour cell content (i.e., the level of
contaminative normal tissue present in the sample) and the tumour tissue heterogeneity
should be considered while analyzing the results of aCGH, as they might cause variation
in the estimates of copy numbers. Figure 7 demonstrates an example of oncogene
amplification detected by aCGH.
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Figure 7: aCGH analysis by CGH analytics software of a gastric cancer sample,
indicating a high level amplification of the proto-oncogene ERBB2 and 10 other genes
located on region 17q21.1 (Vauhkonen et al, unpublished data). Base pair positions from
pter to qter are indicated on the X-axis and the intensity ratios indicating copy number
fold changes are shown on the Y-axis (for example +2X represents a 2-fold increase as
compared to normal level).
5.2. Tumour suppressor gene inactivation by DNA copy number loss
Tumour suppressor genes constrain cell growth. Therefore, the loss of their function
releases the growth constraints, leading to uncontrolled cell growth. Based on
epidemiologic studies, Alfred Knudson (1971) proposed the ‘two-hit’ hypothesis in the
development of retinoblastoma, an aggressive childhood eye tumour. According to his
theory ‘two hits’ or mutagenic events are required to inactivate the tumour suppressor
alleles. In familial cancers one hit is inherited through the germline and a second somatic
0
2X
4X
16X
-16X
-4X
-2X
0
2X
4X
16X
-2X
-4X
-16X
30
mutation is needed, whereas in sporadic cancers both mutations are somatic. The
functional suppression of both alleles is required for the tumour suppressor gene to lose
its ability to inhibit the malignant transformation of the cell. In addition to copy number
loss, tumour suppressor genes can be inactivated by mutations (Lengauer et al. 1998;
Futreal et al. 2004), loss of heterozygosity (Cho and Vogelstein 1992; Koorey and
McCaughan 1993), and by methylation of the promoter region (Jones and Baylin 2007;
Nephew and Huang 2003). Deregulated cell growth is the final result of multiple
sequential alterations in both oncogenes and tumour suppressor genes (Lengauer et
al.1998). An example of a loss and microdeletion is shown in Figure 8, which depicts the
powerful resolution of aCGH for detecting both losses and microdeletions, which are
beyond the resolution of cCGH. Well-known proto-oncogenes and tumour suppressor
genes involved in tumourigenesis that are activated and inactivated by copy number
amplifications and losses are listed in Table 8.
Table 8: Well-known oncogenes and tumour suppressors amplified and lost in various
cancers.
Oncogenes Cancer type References
ERBB2 Breast, ovarian Slamon et al. 1987
MDM2 Sarcoma Leach et al. 1993
MYCN Neuroblastoma Schwab 1993; Seeger et al. 1985
AKT2 Ovarian cancer Cheng et al. 1992
Tumour suppressors
TP53 Various cancers Donehower et al. 1992; Livingstone
et al. 1992
BRCA1 Breast and ovarian cancer Katsama et al. 2000; Rio et al. 1998
APC Colorectal cancer Flintoff et al. 2001; Su et al. 2000
DCC Colorectal cancer Cawkwell et al. 1994; Gerdes et al.
1995
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Figure 8: DNA copy number loss of various genes and microdeletions at 9p21.3
harbouring CDKN2A and MTAP detected by aCGH in an acute lymphoblastic leukaemia
patient (Usvasalo, unpublished data). Base pair positions from pter to qter are indicated
on the X-axis and the intensity ratios indicating copy number fold changes are shown on
the Y-axis (for example +2X represents a 2-fold increase as compared to normal level).
5.3. Pathway analysis based on aCGH data
Cancer is a complex genetic disease and genes operate through the interaction of various
pathways. Although individual genes with copy number changes may allow the
progression or initiation of tumours, these copy number changes ultimately affect their
protein products and their functions. These proteins do not operate on their own, but
rather are involved in large interaction networks, or pathways, to achieve a particular role
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at the cellular level. It is hence highly useful to study copy number alterations in terms of
biologically meaningful pathways, rather than the traditional approach at the single gene
level. Pathway level analysis thus provides a more comprehensive view of the biological
mechanisms underlying the disease.
High-throughput technologies such as aCGH generate large-scale, genome-wide datasets
regarding gene copy number changes. Sets of affected genes can be assessed for
statistical significance using a variety of methods, the majority of which evaluate the
degree of enrichment relative to what is expected by chance. There are many tools
available on-line for performing this type of analysis (http://www.geneontology.org
/GO.tools.shtml), one of the feature-rich tools used in Study V being WEBGESTALT
(Zhang et al. 2005). Figure 9 shows an example of an analysis result, displayed as an
acyclic graph, generated by WEBGESTALT for the genes gained in ULMS using
pathway definitions provided by the Gene Ontology (GO) consortium
(http://www.geneontology.org). A number of pathways belonging to the biological
processes category were identified to be significantly affected, Figure 9 showing a few of
the pathways affected by copy number gains.
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Figure 9: Pathway analysis on the genes affected by copy number gains performed by
WEBGESTALT tool. The figure depicts the partial acyclic graph for pathways under the
biological processes category. Listed in the boxes are the pathway names provided by
GO, the number of genes affected and the P-value from the statistical test for enrichment.
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AIMS OF THE STUDY
The aim of the present Study was to analyse the DNA copy number changes in selected
types of rare soft tissue sarcomas and osteosarcoma using high-throughput microarray
comparative genomic hybridization (aCGH) technology.
The specific aims were:
a) To screen novel gene copy number changes and detect precise boundaries
of gene copy number aberrations and characterize their target genes in soft
tissue leiomyosarcoma, dermatofibrosarcoma protuberans and osteo-
sarcoma (I, II, III).
b) To uncover the biological networks involved in the malignant progression
of uterine leiomyosarcoma (V).
c) To characterize the 17p amplicon shared by leiomyosarcoma, malignant
fibrous histiocytoma and osterosarcoma (IV).
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MATERIALS AND METHODS
1. Sarcoma specimens and DNA extraction (I-V)
In Study I: Fourteen formalin-fixed paraffin-embedded tissue sections from primary
LMS from 14 patients were collected from the Helsinki University Central Hospital,
Helsinki, Finland. Appropriate immunohistochemical analyses and histopathologic
reviews were performed to confirm the diagnoses. The Scandinavian Sarcoma group
grading  system was  applied  where  tumours  were  classified  as  low grade  (I-II)  or  high
grade (III-IV). Among these 14 samples, 3 were low-grade with changes in chromosome
17p, 4 were low-grade without changes in chromosome 17p, 3 were high-grade with
changes in chromosome 17p, and 4 were high-grade without changes in chromosome
17p. For aCGH analysis samples were pooled (Table 9) into four categories according to
the grade and changes in chromosome 17p.
     Table 9: Details of the 4 pools used in Study I.
Pool A (case 1-3) Low-grade LMS with changes in chromosome 17p
Pool B (case 4-7) Low-grade LMS without changes in chromosome 17p
Pool C (case 8-10) High-grade LMS with changes in chromosome 17p
Pool D (case 11-14) High-grade LMS without changes in chromosome 17p
In Study II: Six formalin-fixed paraffin-embedded tissues from DFSP specimens were
collected from the Orthopedic Centers at the Helsinki University Central Hospital,
Helsinki, Finland and 4 frozen samples were obtained from the Lund University Hospital,
Sweden. Re-evaluation of the diagnosis was done by histological examination and
immunohistochemistry using CD34 antibody.
In Study III: Twenty-one fresh frozen OS samples (14 conventional, 2 soft-tissue, 3
periosteal, 1 fibrohistiocytic and 1 small cell OS) were collected from Helsinki
University Central Hospital, Helsinki, Finland, and one cell line was obtained from the
Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy.
In Study IV: Formalin-fixed paraffin-embedded tissue sections from 2 low- grade and 2
high- grade soft tissue LMS, 3 high-grade OS, and 2 high-grade MFH were obtained
from Helsinki University Central Hospital, Helsinki, Finland. The samples selected for
the study showed gains in chromosome 17p as revealed by cCGH analysis.
In Study V: Eighteen formalin-fixed paraffin-embedded tissue sections from 18 primary
ULMS samples from 18 Finnish patients were obtained from Helsinki University Central
Hospital, Helsinki, Finland. Of these 18 samples, 8 were low-grade and 10 were high-
grade LMS. Grading was done as described in Study I. Diagnosis and grading was
confirmed by histopathological analyses.
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All the above-mentioned primary sarcomas selected for these studies were collected from
untreated patients. Clinical data of the sarcoma entities is shown in Table 10.
DNA was extracted using standard protocols (Miller et al. 1988; Sambrook et al. 1989).
Reference DNA used in both chromosomal and array comparative genomic hybridization
was extracted from pooled peripheral blood samples (male and female pool) of healthy
individuals.
2. Chromosomal comparative genomic hybridization (I-V)
In order to determine the genome-wide DNA copy number changes at the chromosome
level, cCGH was performed on all the sarcoma samples from Studies I to V. The protocol
for cCGH was according to the method described by Kallioniemi and co-workers (1992,
1994) with slight modifications (El-Rifai et al. 1997). Briefly, tumour DNA and
reference DNA were labeled by nick translation. Equal amounts of tumour DNA labeled
with fluorescein isothiocyanate FITC-dCTP and FITC-dUTP (1:1; DuPont, Boston, MA,
USA) and reference DNA labelled with Texas-Red-dCTP and Texas Red-dUTP (1:1;
DuPont), along with unlabeled Cot-1 DNA to block the binding of repetitive DNA
sequences, were hybridized onto normal metaphase spreads. After 48-hour hybridization
at 37°C, the slides were washed and counterstained with DAPI in an antifading solution.
An Olympus fluorescence microscope and the ISIS digital image analysis system
(Metasystems GmbH, Altlussheim, Germany) were used to analyse the hybridized slides.
For each sample, three-colour images of 10-12 good quality metaphases were taken.
Changes in the chromosomal regions were interpreted by calculating the signal intensity
ratios of red to green colours along each chromosome. The cut-off value for gains was
defined as when the ratio exceeded 1.17, losses when the ratio fell below 0.85, and high-
level amplification when the ratio exceeded 1.5.
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Table 10: Clinical data of the sarcomas cases analysed in Studies I-V.
Case/Study/
tumour type
Sex/
age
Grade Tumour
site/size (cm)
Case/Study/
tumour
type
Sex/
age
Grade Tumour
site/size (cm)
1/I/LMS F/44 LG Subcutaneous/6.0 1/IV/LMS M/36 LG Cutaneous/1.2
2/I/LMS M/36 LG Cutaneous/1.2 2/IV/LMS F/64 LG Subcutaneous/3
3/I/LMS F/64 LG Subcutaneous/3.0 3/IV/LMS F/80 HG Subcutaneous/2
4/I/LMS M/57 LG Cutaneous/2.0 4/IV/LMS M/46 HG Cutaneous/2.3
5/I/LMS M/78 LG Cutaneous/0.7 5/IV/OS M/31 HG Femur/NA
6/I/LMS F/25 LG Cutaneous/1.0 6/IV/OS F/22 HG Femur/NA
7/I/LMS M/65 LG Cutaneous/0.9 7/IV/OS M/16 HG Femur/NA
8/I/LMS F/80 HG Subcutaneous/2.0 8/IV/MFH F/63 HG Soft tissue/NA
9/I/LMS M/61 HG Deep/8.0 9/IV/MFH M/64 HG Soft tissue/NA
10/I/LMS M/46 HG Cutaneous/2.3 1/V/ULMS F/64 LG Uterus/10
11/I/LMS F/91 HG Subcutaneous/13 2/V/ULMS F/75 LG Uterus/7
12/I/LMS F/55 HG Subcutaneous/2.0 3/V/ULMS F/42 LG Uterus/5
13/I/LMS F/77 HG Deep/6.0 4/V/ULMS F/40 LG Uterus/5
14/I/LMS M/35 HG Deep/10 5/V/ULMS F/48 LG Uterus/NA
1/II/DFSP M/27 NA Forearm/2.8 6/V/ULMS F/49 LG Uterus/6
2/II/DFSP M/46 NA Groin/7 7/V/ULMS F/34 LG Uterus/4
3/II/DFSP M/28 NA Chest/2 8/V/ULMS F/69 LG Uterus/NA
4/II/DFSP M/40 NA Back/6 9/V/ULMS F/58 HG Uterus/4
5/II/DFSP M/52 NA Scalp/NA 10/V/ULMS F/71 HG Uterus/>20
6/II/DFSP F/36 NA Back/8 11/V/ULMS F/70 HG Uterus/NA
7/II/DFSP M/42 NA Arm/7 12/V/ULMS F/64 HG Uterus/5
8/II/DFSP M/56 NA Groin/4 13/V/ULMS F/38 HG Uterus/4
9/II/DFSP M/60 NA Abdominal/4 14/V/ULMS F/64 HG Uterus/8
10/II/DFSP M/64 NA Shoulder/11 15/V/ULMS F/69 HG Uterus/NA
1/III/OS M HG Cell line/NA 16/V/ULMS F/38 HG Uterus/>20
2/III/OS M/27 HG Femur/NA 17/V/ULMS F/53 HG Uterus/10
3/III/OS M/31 HG Femur/NA 18/V/ULMS F/81 HG Uterus/14
4/III/OS M/18 HG Femur/NA
5/III/OS F/19 HG Femur/NA
6/III/OS M/37 HG Femur/NA
7/III/OS M/45 HG Tibia/NA
8/III/OS M/16 HG Femur/NA
9/III/OS F/48 HG Femur/NA
10/III/OS F/16 HG Tibia/NA
11/III/OS M/23 HG Femur/NA
12/III/OS F/22 HG Femur/NA
13/III/OS M/22 HG Femur/NA
14/III/OS F/19 HG Femur/NA
15/III/OS F/32 HG Femur/NA
16/III/OS M/63 HG Femur/NA
17/III/OS F/77 HG Femur/NA
18/III/OS F/25 HG Femur/NA
19/III/OS M/44 HG Femur/NA
20/III/OS F/91 HG Femur/NA
21/III/OS F/21 LG Femur/NA
22/III/OS M/19 HG Femur/NA
LG=low-grade; HG=high-grade; NA= Not available
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3. Array comparative genomic hybridization (I-V)
DNA copy number changes at the gene level were detected by performing high-
resolution genome-wide aCGH in all Studies (I-V). Due to the rapid development of the
aCGH technology, three different array platforms were used. cDNA arrays containing
13,000 clones (Agilent Technologies, Palo Alto, CA, USA) were used in Studies I, II and
III. Customized cDNA arrays containing 16,000 clones (http://microarrays.btk. utu.fi) in
Study V and oligonucleotide arrays with 44,000 targets (Agilent Technologies) in Study
II and IV were used to perform the array experiments. In order to avoid the detection of
copy number polymorphisms in the reference sample, pooled sex-matched reference
(female reference for female sample) DNA samples were used. Performing four sex-
mismatched and sex-matched normal versus normal hybridizations validated the quality
of arrays. The quality of genomic DNA has a substantial effect on the data, thus quality
and purity of the DNA was measured by gel electrophoresis and optical density,
respectively. For the oligonucleotide arrays, quantification of the labelled genomic DNA
was performed using an ND-1000 Spectrophotometer (NanoDrop Technologies,
Rockland, DE). aCGH on cDNA arrays was conducted according to the protocol
described by Pollack et al. (1999) and Monni et al. (2001), with slight modifications. For
cDNA arrays, 6.0 ?g of AluI and RsaI digested genomic DNA, and for oligonucleotide
arrays 1.5 ?g of digested DNA, were used for the hybridization. The DNA was labeled
by random priming reactions. Tumour and reference DNA were labeled with Cy5-dUTP
and Cy3-dUTP, respectively (Amersham Biosciences, Piscataway, NJ). Hybridizations
and washing of 13K  and  16K  cDNA  slides  were  performed  as  described  elsewhere
(Monni et al. 2001), with minor changes in the duration of washes. Microarray slides
were then dried and scanned using a laser confocal scanner (Agilent Technologies) to
measure the signal intensities. Agilent’s Feature Extraction software was used to extract
the data from the microarray images. Agilent oligonucleotide arrays were performed
following the manufacturer’s instruction (Aligent Technologies).
4. Data analysis (I-V)
For 13K and 16K cDNA arrays (Studies I and II) DNA copy number aberrations and
their associated breakpoints were identified, in addition to visual analysis, with aCGH-
smooth software (Jong et al. 2004). For oligonucleotide arrays (Studies II and IV) CGH
analytics software (Agilent Technologies) was used. For Study III the thresholds for
gains (1.3) and losses (0.7) were defined by self versus self hybridizations. GeneSpring
7.2 software (Redwood City, CA) for filtering the data and CGH-explorer 2.5 for the
identification of gains and losses at a false discovery rate of 1% were used in Study V.
Genomic base-pair localizations for each cDNA clone for both the 13K and 16K cDNA
arrays were retrieved from the University of California Santa Cruz Genome Browser
database (http://www.genome.ucsc.edu/) as described previously by Hyman and co-
workers (2002). In Study V, biologically relevant associations for the statistically
significant gained or lost genes were assessed using the WEBGESTALT tool
(http://bioinfo.vanderbilt.edu/webgestalt/).
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5. Statistical analysis (V)
Multivariate statistics were used in Study V for assessing patterns of DNA copy number
changes for association with clinical parameters i.e., tumour grade, tumour size, and the
patients’ last follow-up.
6. Ethical permissions (I-V)
For Study I and Study V ethical permissions were granted by the Ethics Review Board,
Department of Surgery, Hospital District of Helsinki and Uusimaa (610/E6/2001) and the
National Authority for Medicolegal Affairs (1745/32/300/03). The HUS coordinating
Ethics Review Board HUS 328/E0/05 and HUS 329/E0/05 (both on 27.9.2005) granted
permission for Studies II, III and IV.
RESULTS
1. DNA copy number profiling of sarcomas (I-III)
In Studies I-III, 14 low- and high-grade LMS, seven DFSP and 22 OS cases were
analysed by aCGH. Due to the rapid development in microarray technology, three
different platforms were used. In Studies I and III 13K arrays were used, and in Study II
13K, 16K and 44K arrays were used.  The aCGH results of Studies I-III are summarized
in Table 11 and Figure 10. In Study III losses and gains were excluded from the analysis,
as the main focus was to identify recurrent amplicons and the target genes therein. The
gains/amplifications seen in at least 20% of the sarcomas were at chromosomes 6p12-
p21, 8q, 12q11-q15, 17 and 22q. Of these recurrent changes, amplifications of 6p12-p21,
8q, and 12q11-q15 were restricted to OS, while gain/amplification of 17 were seen in
DFSP, OS, and LMS. Gain/amplification of 22q occurred in DFSP and OS.
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Table 11: DNA copy number changes detected by aCGH in LMS, DFSP, and OS. DNA
copy number gains and losses are marked with (+) and (-), amplification is indicated in
boldface. In Study III only amplifications were scored.
      LMS
Study/case DNA copy number changes
I/pool A -2p25, -6p12-pter, +6p12-qter, -10q26.3-qter, -12p13.3, -13q14-q34, +15q26,
+17p13.1-q11, -19q13.33-q13.43, -22q11.21
I/pool B -13q11-qter
I/pool C +10pter-q11.22, -10q11.22-q24.3, -13q14.3-q34, +15q11-q26.3, +17p13.1-q11,
-17q25.3 +19p13.2-p13.3, +20p11,  -Xq13.2-q28
I/pool D -6p21-q26, -10p12.32-pter,  +20pter-q11.2, + 20q13-qter
     DFSP
II/2 +5q35.3, +17q23.2-qter, +18q21.1-q21.3, +19q12-pter, + 22q22.3
II/3 +3p21.31-p21.1, +8q24.3, +17q21.33-qter, +20q13.33, +22cen-q13.1
II/6 +1p35.3-pter, +1q21.2-qter, +17q21.31-q25.3/17q24.1-q25.3, +18q21.33-pter, + Xq28
II/7 +11p15.5, + 17q23.2-qter, -22q13.2-qter
II/8 +17q24.2-qter
II/9 +6p21.2-p21.3, +17q21.2-qter, +19q13.1-q13.2, +19q13.42-q13.43, 22cen-q13.1
II/10 +8q24.2-q24.3, +13q34, +17q21.32-qter, + 22cen-q13.1
     OS
III/1 +6p12-p21, +7q31-q34, +9p13,  +12p13, +17p
III/2 +8p11, +17q25
III/3 +3p25, +5p, +6p12-p21, +7q31-q34, +8q, +15q23-q26, +16q12-q24, +17p, +18q,
+17q25, + 21q22
III/5 +1p36, +12q11-q15, + 19q13, +20q
III/6 +12q11-q15
III/8 +17p, +19q13
III/10 +8q
III/11 +1p13, +1q21, + 6p12-p21, +7q22, +8q, +9q34,  +11q13, +12q11-q15, +14q11,
+16p13, +20q, +17q25, +19q13, +21q22, +22q
III/12 +12q11-q15, +17p
III/13 +1p22, +1q21, +1q23, +8q, +6p12-p21
III/14 +2q11-q12
III/15 +12p13, +12q11q15, +14q11
III/16 +2p11, +4p12-q12, +8q, +14q11, +15q23-q26, +20p11-p12
III/17 +1p36
III/18 +5p12-p15, +8q, +19p13
III/19 +1p34-p36, +1q11-q24, +12q11-q15,  +16p12-p13, +19p12, +19q13, +20p12,
+20q12, +21q12, +22q12
III/20 +12p13, +12q11-q15,+14q11, +22q
III/21 +12q11-q15
III/22 +1p13, +1q32, +1q21, +6p12-p21, +22q
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Figure 10: A summary of DNA copy number changes throughout the genome detected by
aCGH in low- and high-grade LMS (14 cases), DFSP (7 cases), and OS (19 cases).
Losses are marked as areas drawn on the left side of the chromosome idiogram, and
gains on right side. Amplifications are shown as darker areas on the right side.
Chromosomal idiogram was generated with the profilebase software
(www.progenetix.net). The three vertical thin lines at the left and right of the
chromosome idiogram indicate the frequency of losses and gains at cut-off of 5%, 10%,
and 20%, respectively.
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2. Association of DNA copy number changes in ULMS to biological processes and the
clinical data (V)
aCGH analysis on 18 ULMS cases using customized 16K microarrays revealed a
complex pattern of copy number changes in all chromosomes with a slightly higher
proportion of losses than of gains. After rigorous filtering of the data, bringing the
number of genes included for statistical analysis down to 10,590 genes, 4,387 and 4,518
genes were detected gained and lost, respectively, in at least one case. As the aim of the
Study was to focus on the more representative aberrations for ULMS, the loci affected in
at least 20% of cases were considered, resulting in 231 and 265 genes being identified as
gained or lost. In order to obtain a more expansive view of the biological processes
affected by the underlying complex aberration pattern, pathway analysis was additionally
performed. A high proportion of genes with DNA copy number gains and losses were
observed for a number of pathways in the biological processes defined by GO. The most
intriguing pathways affected by copy number changes, with obvious relevance to cancer
development and/or progression, are listed in Table 12.
Multidimensional scaling analysis was performed in order to detect any correlation
between DNA copy number change and clinical parameters such as tumour grade,
tumour size, and status at last follow-up. No evidence of correlation between aberration
patterns and clinical parameters were detected.
Table 12: Some of the pathways affected by copy number gains and losses.
Gains Pathways affected Losses Pathways affected
1p22, 1q12-
q32, 2p23.3,
3p24-p26,
6p21.3,
8q22-q24,
10q26,
18p11.32
G1/S transition of mitotic
cycle (p=0.016), co-
translational protein
targeting to membrane (p=
0.006), actin filament
polymerization (p=0.016),
positive regulation of
cytokine biosynthesis
(p=0.018)
2q33.1, 4q13-q35, 6p21,
6q14.1, 7p15.2, 7q22.1,
13q11-q31, 14q32.3,
16q22-q24, 19p13,
Xp22.3, Xq26-q28
DNA replication (p=
0.021), chromatin
modification
(p=0.017), telomere
maintaining (p=
0.006), meiosis
(p=0.020), mitosis
(p=0.036),
angiogenesis
(p=0.040)
3. Characterization of the copy number changes in the p-arm of chromosome 17 by
aCGH (IV)
The detailed DNA copy number aberrations in chromosome 17p were analysed by
oligonucleotide-based aCGH in nine cases belonging to three sarcoma entities (OS, LMS,
MFH). The inclusion of samples was based on gains at 17p detected by previous cCGH
analysis. As shown in Figure 11, in all cases except for one case of MFH (case 8), the p
arm of chromosome 17 started with a p-terminal loss, TP53-C17orf25 being the minimal
common lost distal region and TP53-GAS7 the minimal common proximal lost region.
The aforementioned p-terminal losses were followed by gains and amplifications in all
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cases. Copy number losses detected by aCGH were not detected by cCGH due to the
restricted resolution of this technique. Gains and amplifications in 17p11.2-p12 were
detected in all samples, containing 63 genes spanning from FLJ45455 to ULK2. Low-
grade LMS and MFH showed a continuous copy number pattern at 17p11.2-p12, whereas
high-grade LMS and OS showed a discontinuous pattern.
.
Figure 11: Fine structure of 17p DNA copy number changes found by aCGH in low- and
high-grade LMS (cases 1-4), OS (cases 5-7) and MFH (cases 8-9). Thin lines indicate
losses, dotted lines indicate gains and bold lines indicate amplifications.
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DISCUSSION
1. Impact of aCGH technology in understanding sarcomas (I-V)
aCGH has been used in various cancers as a tool for measuring copy number status of
tumour DNA. The aim of the present work was to apply aCGH as a tool to screen novel
DNA copy number aberrations and the genes involved in these aberrations in sarcomas
not detectable by low-resolution cytogenetic methods, thereby gaining new insights into
the molecular genetic changes that occur in sarcomas. Further aims were to to identify the
tumour-specific copy number changes and the genes therein with accurate breakpoint
boundaries, which are not precisely detected by cCGH. This Thesis provided new
information regarding the precise DNA copy number changes, thus adding new
information to results previously described by others. The novelty of this Thesis lies in
providing information regarding the biological pathways involved in pathogenesis for
some sarcoma entities. Thus, application of the aCGH technique in the rare sarcomas
studied in this Thesis proved to be highly relevant in identification of potential target
genes for further studies and also in understanding the biology of sarcomas.
 In Studies I-V aCGH was applied to the DNA obtained from fresh frozen and paraffin-
embedded tissue. Regardless of the DNA source, successful aCGH results were obtained
from all samples. Thus, Studies I-V demonstrated the applicability of the enhanced
resolution achieved by aCGH, which enabled the identification of precise boundaries of
copy number changes and their breakpoints, candidate cancer related genes, and detection
of recurrent aberrations. As an example, Figure 12 demonstrates the aCGH results of
low-grade LMS. Fold level changes in signal intensity, reflecting copy number losses and
gains, and the genes that occur within these regions are indicated. Accordingly, the
results demonstrated the power of aCGH to provide the in-depth information of
aberrations regarding the genes and the breakpoints of chromosomal gains, losses, and
amplifications.
In Study I, gene copy number profiling of low- and high-grade LMS by aCGH was
conducted for the first time, highlighting the differences and similarities between the two
tumour grades.
The recently developed 60-bp oligonucleotide microarrays need very little DNA (1.???g)
allowing the analysis of individual tumours, which is sometimes not possible with cDNA
arrays  where  20??g of DNA is required as the starting material for the analysis.
Oligonucleotide arrays were used in Study IV and their high resolution provided in-depth
information regarding the 17p amplicon structure in sarcomas. One of the most striking
findings by aCGH in this Study was the copy number loss before the 17p amplicon that
has not been observed by cCGH due to its limited resolution. Copy number profiling of
17p done in this Study for MFH and LMS, to our knowledge, has never been previously
reported. Study V provided in-depth information regarding the various, not previously
reported, biological pathways that were altered by copy number changes.
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Figure 12: DNA copy number losses and gains detected in chromosome 17p in low grade
LMS. aCGH detects both genes and the breakpoint region involved in the aberrations.
On the Y-axis zero indicates the baseline and intensity ratios indicating copy number fold
changes are shown (for example +2X represents a 2-fold increase as compared to
normal level). Base pair positions are indicated on the X-axis.
In this Thesis aCGH analyses were performed on only a small number of cases from each
sarcoma entity due to the rarity of these sarcomas. Nevertheless, aCGH analysis provided
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the leads to the identification of target genes that in the future need to be further
investigated. Details of these results are discussed below.
2. High-  and low-grade LMS show distinctive aberration patterns (I)
aCGH was performed on 13K arrays, which require ????g of DNA as starting material.
As there was not enough tissue to meet the requirements for making individual arrays, the
DNA of individual samples was pooled. Use of sample pools in microarray experiments
in order to detect relevant changes common to all samples has been successfully applied
in many microarray studies (Craig et al. 2005; Kendziorski et al. 2005; Zhang and Gant
2005a). However, the small changes that vary from case to case remain undetected in
sample pools. aCGH detected two common regions of gains (15q26-qter and 17p13.1-
q11) and two of losses (6p12-p21.3 and 13q14.3-qter) which were shared between low-
and high-grade LMS, and nine and 12 different regions altered only in the low- and high-
grade sample pools, respectively. All of these regions were undetected by cCGH, thus
aCGH proved to be an effective tool in differentiating between low- and high-grade LMS
based on their aberration patterns. More gains (three-fold) were detected in high-grade as
compared with low-grade LMS, and the numbers of losses were about two-fold higher in
low-grade as compared to high-grade LMS. This might indicate that losses are the
initiation factor for tumourigenesis and that gain is required for tumour progression.
17p13.1-q11 was gained in both low- and high-grade LMS, which supports previously
published data which indicates that gain of this region is a frequent phenomenon in LMS.
Pools of low- and high-grade LMS with changes in chromosome 17p showed a large
number of aberrations as compared to low- and high-grade pools without changes in
chromosome 17p. This might suggest that tumours with changes in chromosome 17p are
more complex and that the region might contain some important genes which cause the
complexity in the karyotype.
3. aCGH detected the exact translocation breakpoints at the  exon level in DFSP (II)
The characteristic feature of DFSP is a translocation, t(17;22)(q22;q13.1), that is most
often unbalanced, resulting in the fusion of COL1A1 and PDGFB. The major advantage
of aCGH performed on high-resolution (60 bp) 44K chips lies in the knowledge of the
exact base pair location for every probe. Previous analysis has shown the chromosome
band 17q22 as the location for COL1A1 and 22q13 as the location for PDGFB. By aCGH
analysis 17q21.33 was defined as the breakpoint region for COL1A1 and 22q13.1 for
PDGFB. It was earlier reported that the location of the breakpoint within COL1A1 varies
greatly whereas PDGFB has a constant breakpoint (O'Brien et al. 1998). By the aCGH
approach the detection of the exact breakpoint within the COL1A1 gene became possible.
Recurrent gains of 17q21.33-qter and 22q-q13.1 could be seen by aCGH, consistent with
previous cCGH studies (Kiuru-Kuhlefelt et al. 2001;  Nishio et  al. 2002; Sirvent et al.
2003). aCGH analysis thus provided  novel information about the genes involved in the
gained regions, which need to be further investigated. DNA copy losses in DFSP were
not as frequent as in other sarcomas. In one case aCGH detected loss in 22q13.2-qter that
might indicate an unbalanced translocation. This terminal loss had previously been
identified by Buckley and co-workers (2002) in two DFSP tumours using chromosome
22 BAC arrays. Exact breakpoints and the genes involved were determined for the
47
additional changes reported by aCGH in Study II that might be involved in the
pathogenesis of DFSP.
4. aCGH defined 12q11-q15, 8q, 6p12-p21 and 17p as recurrent amplicons in OS (III)
In contrast to some other sarcoma entities that are associated with some specific, well-
defined chromosomal translocations, OS presents a unique challenge as it lacks any
recurrent translocation or chromosomal changes, and possesses instead multiple
chromosomal abnormalities. This Study aimed to analyse only the recurrent amplicon and
their target genes, which might lead to the identification of the target genes driving the
amplifications. aCGH detected recurrent amplicons with high levels of amplification at
12q11-q15, 8q, 6p12-p21, and 17p, and less frequent small amplicons showing lower
levels of amplification at 1p34-p36, 1q21, 19q13, and 21q22. These amplicons had
discontinuous structures accompanied by DNA copy number losses, gains and no copy
number changes. These amplicons have been also detected in previous studies by cCGH
(Sandberg and Bridge 2003b).
The amplicons at 12q and 17p were further analysed in detail as these amplicons
contained genes with very high copy numbers ratios and were recurrent in all the
samples. The possible target genes of amplicon 12q, based on the very high amplification
ratios, were OS9, CYP27B1, DKFZP586D0919, and TSFM. Genes such as COX10,
PMP22, ADORA2B, ZNF287, MRIP, COPS3, PEMT, SREBF1, TOM1L2, TOP3A, GRAP
and MAPK7 were considered as possible targets within the 17p amplicon, as these were
the most recurrent genes gained in all samples. Some of the target genes amplified in our
Study has also been detected in other studies (van Dartel et  al. 2002). Based on
expression profiling of an OS cell line (Monni et al personal communication), TOM1L2
could be considered as a candidate target gene since this gene was both amplified and
expressed. TOM1L2 is involved in intracellular protein transport (http://www.
geneontology.org). Further studies are needed to investigate the role of the other possible
target genes mentioned in order to understand the contribution of those genes in OS.
5. aCGH highlights the involvement of various cellular pathways in ULMS (V)
To understand the various biological processes underlying cancer, pathway analysis
based on gene expression data has been extensively used in various cancers (Furge et al.
2007; Hong et al. 2007; Oishi et al. 2007). To date, studies adopting similar analysis
techniques for aCGH data are scarce, especially regarding ULMS. To our knowledge
there is, in fact, only one such study, limited to only seven ULMS tumours and using a
lower resolution BAC-based array (Cho et al. 2005). Accordingly, in the present Study
the GO classification system (http://www.geneontology.org) was used to describe the
pathways that were ascribed to the gained or lost genes. GO provides a formal, controlled
and precisely defined vocabulary in order to describe the roles of genes or gene products
in organisms. The GO definitions are organized into three categories: molecular function,
biological processes and cellular component. By analyzing the complex patterns of copy
number gains and losses by adopting a pathway approach, we aimed to gain
understanding about the cellular mechanisms that underlie ULMS. The idea was that the
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analysis results would not only help to pinpoint the processes implicated in the
development and/or progression of the cancer, but also shed some light on the resistance
of ULMS to both radiotherapy and chemotherapy. Our approach provided results that are
biologically interpretable and statistically robust. Various biological processes were
identified as being statistically significantly affected by gene copy number gains and
losses, of which perhaps the most striking were chromatin modification, mitosis, DNA
replication, meiosis, angiogenesis, and G1/S transition of mitotic cycle. These pathways
featured two well-established tumour suppressor genes (BRCA2, EREG) and one proto-
oncogene (GFI1). These findings provided a clear view of the various deregulated
biological pathways, such as DNA replication, chromatin modification, telomere
maintenance, meiosis and mitosis, among others, which might contribute to the
tumourigenesis in ULMS.
The aberration patterns showed no correlation with clinical parameters, as observed also
in previous studies including various types of sarcomas (Mandahl et al. 2000).
6. DNA copy number changes of 17p in sarcomas (IV)
Amplification or gains in the p arm of chromosome 17 is a characteristic feature shared
by sarcoma entities such as OS, LMS, and MFH. This might indicate the residence of the
putative oncogene (s) in this zone. A few target genes for OS have been suggested (van
Dartel et al. 2002)  but  no  specific  targets  have  been  defined  for  LMS  or  MFH.  We
applied aCGH to explore the copy number status of chromosome 17 in detail in the
aforementioned sarcoma entities, work previously not done using fine resolution arrays.
Precise boundaries of aberrations were defined. With the exception of one MFH case, all
cases showed losses distal to gains or amplifications. In all cases, a minimal common
region of TP53-C17orf25 was  defined  as  a  distal  region  of  loss  and TP53-GAS7 as  a
proximal region of loss before the gain or amplification. These losses have not been
detected by cCGH method previously, thus aCGH proved to be effective tool for
screening losses and gains upto the kb level, which helps in the characterization of
amplicons. Identification of DNA copy number loss before the 17p amplicon is still an
open question in understanding whether DNA copy number loss is an early initiating
event before the amplification or is a result of the amplification. TP53 functions as a
guardian of the genome, and is involved in pathways including detection of DNA
damage, DNA repair, cell cycle arrest, and apoptosis. It responds to DNA damage signals
by inducing apoptosis and thus maintaining genome integrity (Attardi 2005; Hussain and
Harris 2006; Janus et al. 1999). Deletions at TP53 reported in the mutation database in
MFH, LMS, and OS were at frequencies of 8.43%, 2.73%, and 13.4%, respectively,
whereas point mutations in TP53 were reported with frequencies of 19.2%, 20.5%, and
26.9%, respectively (Olivier et al. 2002).
Based on the copy number profiling at chromosome 17p by aCGH, low-grade LMS and
MFH were grouped together due to the similar continuous pattern of gains, whereas high-
grade LMS and OS were grouped together due to their non-continuous amplification
patterns (Figure 13). Based on aCGH results it can thus be speculated that variation in the
copy number pattern such as continuous and non-continuous gain/amplification patterns
lead to different mechanisms of the establishment of amplicons. In Study III all OS
showed the same starting and ending point for 17p amplicons by 13K arrays. Study IV
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resolved the DNA copy number trend in OS using oligonucleotide arrays and thus
demonstrated a complex amplification pattern interrupted by gains and losses, which
were not detected by the lower resolution 13K arrays. Beside gains/amplification at 17p
in OS, LMS, MFH, complex aberration patterns were observed in these sarcomas. This is
attributed to the breakage-fusion-bridge cycle that is responsible for the chromosomal
instability, by causing excess structural and numerical alterations, gene amplification,
complex rearrangements, ploidy changes and cell-to-cell cytogenetic variation
(Gisselsson et al. 2000).
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Figure 13: Continuous (A) and discontinuous (B) patterns of copy number changes at
17p in low-grade LMS and OS, respectively, detected by aCGH.  On the X-axis the
cytogenetic position of chromosome 17p is shown and on the Y-axis the intensity ratios
indicating copy number fold changes are shown (for example +2X represents a 2-fold
increase as compared to normal levels).
A
B
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CONCLUSIONS
The aim of this Thesis was to detect the DNA copy number changes in soft tissue (LMS,
DFSP, ULMS, and MFH) and bone sarcomas (OS) by high-resolution aCGH. aCGH was
proven to be an effective tool for screening the copy number changes regardless of the
source of the DNA.  aCGH discriminated between low- and high-grade LMS based on
their copy number patterns. In DFSP, 21 changes were detected in addition to the well-
known gains in 17q and 22q. In OS recurrent amplicons were detected at 12q11-q15, 8q,
6p12-p21 and 17p. The target genes identified in the amplicons at 12q and 17q were OS9,
CYP27B1, DKFZP586D0919, and TSFM, COX10, PMP22, ADORA2B, ZNF287, MRIP,
COPS3, PEMT, SREBF1, TOM1L2, TOP3A, GRAP, and MAPK7. The amplicon at 17p
characterized by aCGH in low- and high-grade LMS, OS, and MFH revealed 17p11-p12
as the minimal commonly gained region in all cases. A distal loss at 17p13-pter followed
by gains or amplification was detected in all but one case. A complex pattern of gains and
amplification at 17p separated OS and high-grade LMS from MFH and low-grade LMS,
which showed more continuous regions of copy number gains and amplification at 17p.
In ULMS commonly gained (1p, 1q, 2p, 3p, 6p, 8q, 10q, 18q) and lost (2q, 4q, 6p, 6q, 7p,
7q, 13q, 14p, 16q, 19p, Xp, Xq) regions were identified by aCGH. To understand the
pathogenesis behind these copy number changes, pathway analysis on the genes with
altered copy number changes provided clues to the various biological processes
underlying the tumourigenesis.
For copy number changes analysis beside aCGH, cCGH was also applied in all studies (I-
V)  and  in  Study  II  in  some  cases  G-banding  was  used.  Results  from  all  these  Studies
clearly showed that aCGH detected additional changes undetected by other low-
resolution methods used. aCGH, due to ultra fine resolution, has a promising future in
clinical diagnostics as a powerful tool in scanning the entire genome for DNA copy
number changes and detecting the genes therein, which could be used as specific
markers.
Application of aCGH technology with improved resolution was shown to be an
appropriate method for detecting the exact boundaries of the DNA copy number changes
and the corresponding target genes.  Furthermore, aCGH was also found to be suitable in
providing information regarding the biological processes that were affected by DNA
copy number changes that might be involved in the pathogenesis of sarcomas.
Not all cytogenetic techniques can be used to analyse mesenchymal tumours due to
difficulties in obtaining enough mitoic cells from cell cultures. FISH and RT-PCR are
used to detect specific known genes, but it’s extremely difficult to analyse entire genomes
in a reasonable time. Thus, cCGH and aCGH are only two methods available for genome
wide analysis. aCGH, due to its ultra fine resolution, provides the gene level information
regarding the precise copy number changes and can detect the tumour-specific
markers/genes. Thus, in the future this technique has potential in clinical diagnostics. In
the future FISH, RT-PCR, and tissue microarray analyses are needed to confirm the
present findings on large sample collections and also to determine the clinical
significance of the identified genes. Transcriptomics and proteomics analysis are needed
to understand the biology behind sarcomas and also in identification of target gene
underlying the development/progression of sarcomas, which could lead to the
identification of molecular targets for effective cancer treatment.
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